Latest news with #Bausch+Lomb
Business Wire
5 hours ago
- Business
- Business Wire
Bausch + Lomb Announces Launch of Senior Secured Notes Offering and Refinancing of Credit Agreement
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO) ('Bausch + Lomb' or the 'company'), a leading global eye health company dedicated to helping people see better to live better, today announced that its subsidiaries, Bausch+Lomb Netherlands B.V. and Bausch & Lomb Incorporated (collectively, the 'Issuers'), have launched an offering of €600 million aggregate principal amount of senior secured floating rate notes ('Notes'). In connection with the Notes offering, the company has also launched a partial refinancing of its credit agreement, whereby the company intends to obtain a $2.2 billion new term B loan facility (the 'New Term B Loan Facility') and a new $800 million revolving credit facility (the 'New Revolving Credit Facility'). The company intends to use the net proceeds from the Notes offering and the New Term B Loan Facility, together with borrowings under the New Revolving Credit Facility, to repay certain outstanding borrowings under its existing revolving credit facility, to refinance in full its outstanding term A loans due 2027 and term B loans due 2027, and to pay related fees and expenses, with any remaining amounts to be used for general corporate purposes. The closing of the Notes offering is not contingent upon the closing the New Term B Loan Facility or the New Revolving Credit Facility. The Notes will be guaranteed by the company and each of the company's subsidiaries (other than the Issuers) that are guarantors under the company's credit agreement and will be secured on a first priority basis by liens on the same assets that secure the obligations under the company's credit agreement and the company's outstanding senior secured notes. The foregoing transactions are subject to market and other conditions. There can be no assurance that the company will be able to successfully complete the transactions on the terms described above, or at all. The Notes will not be registered under the Securities Act of 1933, as amended ('Securities Act'), or any state securities law and may not be offered or sold in the United States absent registration or an applicable exemption from registration under the Securities Act and applicable state securities laws. The Notes will be offered in the United States only to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act and outside the United States to non-U.S. persons pursuant to Regulation S under the Securities Act. The Notes have not been and will not be qualified for sale to the public by prospectus under applicable Canadian securities laws and, accordingly, any offer and sale of the Notes in Canada will be made on a basis, which is exempt from the prospectus requirements of such securities laws. This news release is being issued pursuant to Rule 135c under the Securities Act and shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. About Bausch + Lomb Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from birth through every phase of life. Its comprehensive portfolio of approximately 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,500 employees and a presence in approximately 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario, with corporate offices in Bridgewater, New Jersey. Forward-looking Statements This news release may contain forward-looking information and statements within the meaning of applicable securities laws (collectively, 'forward-looking statements'), including, but not limited to, our refinancing plans and the details thereof, including the Notes offering, the New Term B Loan Facility and the New Revolving Credit Facility, the proposed use of proceeds therefrom and the details thereof, our ability to complete the transactions described in this press release, and the other expected effects thereof. Forward-looking statements may generally be identified by the use of the words 'anticipates,' 'seeks,' 'expects,' 'plans,' 'should,' 'could,' 'would,' 'may,' 'will,' 'believes,' 'potential,' 'pending' or 'proposed' and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in Bausch + Lomb's filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators (including the company's Annual Report on Form 10-K for the year ended Dec. 31, 2024 and its most recent quarterly filings). In addition, certain material factors and assumptions have been applied in making these forward-looking statements, including the assumption that the risks and uncertainties discussed in such filings will not cause actual results or events to differ materially from those described in these forward-looking statements. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch + Lomb undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.
Business Wire
4 days ago
- Business
- Business Wire
BLCO Investors Have Opportunity to Join Bausch + Lomb Corporation Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)-- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Bausch + Lomb Corporation ('Bausch + Lomb' or 'the Company') (NYSE: BLCO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Bausch + Lomb reported its financial results for Q1 2025 on April 30, 2025. The Company reported an adjusted net loss of $54 million for the period, as opposed to net income of $24 million in the same period of the prior year. The Company lowered its full-year growth outlook, blaming the change in part on the recall of its enVista product. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Yahoo
03-06-2025
- Business
- Yahoo
1 Safe-and-Steady Stock for Long-Term Investors and 2 to Question
A stock with low volatility can be reassuring, but it doesn't always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere. Finding the right balance between safety and returns isn't easy, which is why StockStory is here to help. That said, here is one low-volatility stock that could succeed under all market conditions and two that may not keep up. Rolling One-Year Beta: 0.91 Notably receiving an order from FedEx for electric vehicles, Shyft (NASDAQ:SHYF) offers specialty vehicles and truck bodies for various industries. Why Do We Think SHYF Will Underperform? Customers postponed purchases of its products and services this cycle as its revenue declined by 13.7% annually over the last two years Capital intensity has ramped up over the last five years as its free cash flow margin decreased by 6.8 percentage points Diminishing returns on capital suggest its earlier profit pools are drying up At $10.40 per share, Shyft trades at 9.7x forward P/E. If you're considering SHYF for your portfolio, see our FREE research report to learn more. Rolling One-Year Beta: 0.66 With a nearly 170-year history dedicated to vision care and eye health innovation, Bausch + Lomb (NYSE:BLCO) develops and manufactures a comprehensive range of eye health products including contact lenses, pharmaceuticals, surgical devices, and consumer eye care solutions. Why Are We Wary of BLCO? Annual revenue growth of 5.3% over the last five years was below our standards for the healthcare sector 20.6 percentage point decline in its free cash flow margin over the last five years reflects the company's increased investments to defend its market position Limited cash reserves may force the company to seek unfavorable financing terms that could dilute shareholders Bausch + Lomb's stock price of $11.45 implies a valuation ratio of 14.5x forward P/E. To fully understand why you should be careful with BLCO, check out our full research report (it's free). Rolling One-Year Beta: 0.58 Founded by Norman Brinker in Dallas, Brinker International (NYSE:EAT) is a casual restaurant chain that operates the Chili's, Maggiano's Little Italy, and It's Just Wings banners. Why Are We Positive On EAT? Same-store sales growth over the past two years shows it's successfully drawing diners into its restaurants Operating profits and efficiency rose over the last year as it benefited from some fixed cost leverage Free cash flow margin increased by 4.2 percentage points over the last year, giving the company more capital to invest or return to shareholders Brinker International is trading at $175.20 per share, or 19x forward P/E. Is now a good time to buy? See for yourself in our in-depth research report, it's free. Donald Trump's victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs. While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today for free. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
22-05-2025
- Business
- Business Wire
Bausch + Lomb to Participate in the 2025 Jefferies Global Healthcare Conference
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Chief Financial Officer Sam Eldessouky is scheduled to participate in the 2025 Jefferies Global Healthcare Conference in New York City on June 4, 2025, at 7:35 a.m. ET. A live webcast of the conference will be available on the Investor Relations section of the Bausch + Lomb website. About Bausch + Lomb Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from birth through every phase of life. Its comprehensive portfolio of approximately 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,500 employees and a presence in approximately 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario, with corporate offices in Bridgewater, New Jersey. For more information, visit and connect with us on Facebook, Instagram, LinkedIn, X and YouTube. © 2025 Bausch + Lomb
Business Wire
21-05-2025
- Business
- Business Wire
Bausch + Lomb Announces 2025 Annual Meeting of Shareholders Results
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO) ('Bausch + Lomb' or the 'Company'), a leading global eye health company dedicated to helping people see better to live better, today announced the election of the 10 directors nominated at its 2025 Annual Meeting of Shareholders (the 'Annual Meeting') held on May 21, 2025. Detailed results of the vote follow: Name For Against Broker Non-Votes 337,617,248 1,924,336 8,383,437 Gary Hu 337,591,706 1,949,878 8,383,437 Brett Icahn 337,474,287 2,067,297 8,383,437 Sarah B. Kavanagh 337,602,211 1,939,373 8,383,437 Karen L. Ling 337,526,114 2,015,470 8,383,437 John A. Paulson 337,650,735 1,890,849 8,383,437 Russel C. Robertson 337,600,880 1,940,704 8,383,437 Thomas W. Ross, Sr. 337,583,018 1,958,566 8,383,437 Brenton L. Saunders 337,592,062 1,949,522 8,383,437 Andrew C. von Eschenbach, M.D. 337,607,276 1,934,308 8,383,437 Expand Shareholders also approved, in a non-binding advisory vote, the compensation of the Company's named executive officers, appointment of PricewaterhouseCoopers LLP to serve as auditor until the close of the Company's 2026 Annual Meeting of Shareholders, and authorization for the board of directors to fix the auditor's remuneration. The final vote tabulation on all matters voted on at the Annual Meeting will be filed with the U.S. Securities and Exchange Commission on a current report on Form 8-K, and such report will be made available on the Company's SEDAR+ profile and on the Company's website at About Bausch + Lomb Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from birth through every phase of life. Its comprehensive portfolio of approximately 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,500 employees and a presence in approximately 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario, with corporate offices in Bridgewater, New Jersey. For more information, visit and connect with us on Facebook, Instagram, LinkedIn, X and YouTube.
